Oral squamous cell carcinoma (OSCC) is one of the most common malignant tumors worldwide. This necessitates the development of innovative drugs with high e

Pyogenic osteomyelitis (POM) presents significant clinical challenges due to persistent infections and impaired bone regeneration. Here, we developed a bacteria-responsive MXene/MoS₂ DNAgel (MXMoS₂ DNAgel) with enhanced photothermal antibacterial capabilities to treat POM. By doping molybdenum disulfide (MoS₂) quantum dots onto MXene nanosheets, the hydrogel exhibited significantly improved near-infrared (NIR) photothermal conversion, facilitating efficient bacterial eradication. The DNA-based hydrogel responded selectively to bacterial DNase, allowing for infection-triggered release of therapeutic components. Furthermore, the MXMoS₂ DNAgel reduced inflammation by modulating macrophage polarization from pro-inflammatory M1 toward anti-inflammatory M2 phenotypes and promoted osteogenic differentiation through activation of the Wnt signaling pathway. Both in vitro and in vivo studies demonstrated excellent antibacterial efficacy, robust bone regeneration, and favorable biocompatibility. Collectively, this multifunctional hydrogel offers a promising therapeutic platform for targeted management and healing of infectious bone diseases.